RE:RE:RE:RE:RE:EY sees bolt-ons in the single to double digit billions now The exclusive licensing agreement that ONCY negotiatied with Adlai Nortye is a "sweet deal" for any Big Pharma acquiring ONCY, should the recently signed POTUS executive order on securing the American Bioeconomy have ONCY's Big Pharma "acquirer" manufacture pelareorep in the United States, ship the finished product to Adlai Nortye for commercialization in China, thus resulting in the ONCY's acquirer eligibility to receive the rewards that come with the US government's monetrary incentives and potential loan foregiveness that backstops any R&D risk, as I posted beforehand.